CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis
Launched by UNIVERSITY OF CAMBRIDGE · Nov 25, 2019
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
The study will take place in three stages; an initial survey, an eight week study period and a follow-up period for an additional eight weeks.
Stage One: Perceptions of Sleep Problems and Their Treatment in Psychosis:
Clinicians and service users will receive an online link to a short 18-question survey (primarily multiple choice) that should take approximately 5 min to complete. Although they can complete this online, a paper copy can be provided if they prefer to handwrite their answers.
Stage Two: Randomised 8 Week Study:
At our initial phone or NHS approved video platform meeting pa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experiencing or having experienced a First Episode of Psychosis (FEP) within the past 5 years.
- • Currently participating in CPFT CAMEO EIPS or NSFT EIS and intending to continue TAU with the specified service for at least the next 4 months.
- • Mental capacity for consent.
- • Currently experiencing threshold level (score ≤ 16 on SCI-8) of disrupted sleep.
- • Adults 18 years or older.
- • Ability to understand and follow therapeutic instructions necessary for experiment and respond to online questionnaires.
- • Illness duration less than or equal to 5 years. Onset of illness was defined as first contact with psychiatric services for psychotic symptoms.
- • Access to the internet.
- Exclusion Criteria:
- • Too unwell to viably participate in study.
- • A diagnosis of drug induced psychosis or bipolar disorder.
- • Psychotic disorder due to a medical or physical disease (i.e. considered to have an organic basis).
- • Current drug or alcohol dependency.
- • Currently taking prescribed sleep medication or intending to do so during study.
- • Currently doing night shift work.
- • Travel over 2 time zones during or within two weeks prior to assessment period.
About University Of Cambridge
The University of Cambridge, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a clinical trial sponsor dedicated to advancing medical science and improving patient outcomes. Leveraging its interdisciplinary expertise and state-of-the-art facilities, the university conducts rigorous clinical trials that explore novel therapies and interventions across a wide range of health conditions. By fostering collaboration between researchers, healthcare professionals, and industry partners, the University of Cambridge aims to translate groundbreaking research into effective clinical applications, ultimately enhancing the quality of care and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, Cambridgeshire, United Kingdom
Patients applied
Trial Officials
Peter B Jones, PhD MD
Principal Investigator
University of Cambridge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials